

**SUPPLEMENT TO MANUSCRIPT:**

**Antidepressant Therapy in Functional Dyspepsia:  
A Multi-Center, Randomized, Controlled Study**

**Supplement Table 1. Adverse Events, n=292**

AE Type	Total (n=292)	Placebo (n=97)	Amitriptyline (n=97)	Escitalopram (n=98)	P-value <sup>§</sup>
<b>Cardiac</b>	4 (1.4%)	2 (2.1%)	0 (0%)	2 (2.0%)	0.55
<b>Dermatologic</b>	11 (3.8%)	8 (8.2%)	0 (0%)	3 (3.1%)	<b>0.007</b>
<b>Endocrine</b>	8 (2.7%)	1 (1.0%)	2 (2.1%)	5 (5.1%)	0.29
<b>Hematologic</b>	1 (0.3%)	1 (1.0%)	0 (0%)	0 (0%)	0.66
Abdominal pain	11 (3.8%)	1 (1.0%)	5 (5.2%)	5 (5.1%)	0.24
Black stools	1 (0.3%)	0 (0%)	1 (1.0%)	0 (0%)	0.66
Bloating	3 (1.0%)	1 (1.0%)	1 (1.0%)	1 (1.0%)	1.00
<i>C. difficile</i> infection	1 (0.3%)	0 (0%)	1 (1.0%)	0 (0%)	0.66
Change in appetite	2 (0.7%)	0 (0%)	0 (0%)	2 (2.0%)	0.33
Constipation	8 (2.7%)	1 (1.0%)	5 (5.2%)	2 (2.0%)	0.23
Diarrhea	4 (1.4%)	1 (1.0%)	2 (2.1%)	1 (1.0%)	0.85
Dry Mouth	2 (0.7%)	0 (0%)	2 (2.1%)	0 (0%)	0.22
Heartburn	2 (0.7%)	1 (1.0%)	1 (1.0%)	0 (0%)	0.55
Hemorrhoids	1 (0.3%)	1 (1.0%)	0 (0%)	0 (0%)	0.66
Intestinal fluid	2 (0.7%)	2 (2.1%)	0 (0%)	0 (0%)	0.22
Liver function abnormality	2 (0.7%)	0 (0%)	1 (1.0%)	1 (1.0%)	1.00
Nausea/Vomiting	18 (6.2%)	3 (3.1%)	6 (6.2%)	9 (9.2%)	0.22
<b>Gastrointestinal</b>	57 (19.5%)	11 (11.3%)	25 (25.8%)	21 (21.4%)	<b>0.03</b>
<b>Gynecologic</b>	2 (0.7%)	0 (0%)	2 (2.1%)	0 (0%)	0.22
<b>Metabolic/Nutritional</b>	4 (1.4%)	3 (3.1%)	0 (0%)	1 (1.0%)	0.23
<b>Musculoskeletal/Skeletal</b>	21 (7.2%)	4 (4.1%)	10 (10.3%)	7 (7.1%)	0.23
Anxiety	12 (4.1%)	4 (4.1%)	2 (2.1%)	6 (6.1%)	0.41
Depression	1 (0.3%)	1 (1.0%)	0 (0%)	0 (0%)	0.66
Dizziness	17 (5.8%)	1 (1.0%)	5 (5.2%)	11 (11.2%)	<b>0.009</b>
Dream abnormalities	1 (0.3%)	0 (0%)	1 (1.0%)	0 (0%)	0.66
Drowsiness or Somnolence	29 (9.9%)	5 (5.2%)	14 (14.4%)	10 (10.2%)	0.09
Headache	13 (4.4%)	3 (3.1%)	2 (2.1%)	8 (8.2%)	0.16
Insomnia	8 (2.7%)	1 (1.0%)	2 (2.1%)	5 (5.1%)	0.29
Tingling	3 (1.0%)	1 (1.0%)	1 (1.0%)	1 (1.0%)	1.00
<b>Neurologic</b>	84 (28.8%)	16 (16.5%)	27 (27.8%)	41 (41.8%)	<b>0.0005</b>
<b>Otolaryngologic</b>	6 (2.0%)	1 (1.0%)	3 (3.1%)	2 (2.0%)	0.70

## Antidepressant Therapy in Functional Dyspepsia

<b>Pulmonary</b>	9 (3.1%)	1 (1.0%)	6 (6.2%)	2 (2.0%)	0.13
<b>Psychiatric</b>	1 (0.3%)	1 (1.0%)	0 (0%)	0 (0%)	0.66
<b>Respiratory</b>	5 (1.7%)	2 (2.1%)	2 (2.1%)	1 (1.0%)	0.75
<b>Sensory Systems</b>	4 (1.4%)	1 (1.0%)	2 (2.1%)	1 (1.0%)	0.85
<b>Urogenital</b>	4 (1.4%)	0 (0%)	4 (4.1%)	0 (0%)	<b>0.02</b>

§ Based on Fisher's Exact test

### Supplement Figure Legends

**Supplement Figure 1.** Gastric emptying before and after treatment (median, interquartile ranges).

There were no differences in baseline solid-phase gastric emptying— $t_{1/2}$  in minutes—between treatment arms. There were also no changes in gastric emptying after treatment in all three treatment arms.

**Supplement Figure 2.** Nutrient drink test satiety test before and after treatment (median interquartile ranges).

The Nutrient Drink Test (NDT) for gastric satiety showed that there were no differences in baseline meal-induced satiety—as measured by maximum tolerated volume (MTV) of Ensure—between treatment arms. There were no changes in gastric satiety after treatment in all three treatment arms.



